|Post IPO Valuation|
|Venture Round, 8/2009 ||$30M|
|Venture Round, 5/2010 ||$21M|
|Venture Round, 8/2010 ||$4.06M|
|Venture Round, 1/2011 ||$25M|
|Debt, 12/2013 |
Hercules Technology Growth Capital
Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkinâ€™s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.